Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Noncontrolling Interest [Abstract]
NCI – equity – December 31, 2022			$ 20,615
Net loss attributable to NCI	$ (3,355)	$ (3,576)	(7,638)	$ (6,337)
Impact of subsidiary equity transactions			(1,332)
Lucid Diagnostics Inc. proceeds from issuance of preferred stock			13,625
Lucid Diagnostics Inc. proceeds from At-The-Market Facilities, net of deferred financing charges			284
Lucid Diagnostics Inc. issuance of common stock for settlement of APA-RDx installment and termination payment			713
Lucid Diagnostics Inc. issuance of common stock for settlement of vendor service agreement			147
Lucid Diagnostics Inc. Employee Stock Purchase Plan Purchase			276
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan			3,982
Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan			10
NCI – equity – June 30, 2023	$ 30,682		$ 30,682